These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25204286)

  • 1. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
    Shin MC; Zhang J; Ah Min K; Lee K; Moon C; Balthasar JP; Yang VC
    J Control Release; 2014 Nov; 194():197-210. PubMed ID: 25204286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.
    Shin MC; Zhang J; Min KA; He H; David AE; Huang Y; Yang VC
    Pharm Res; 2015 Aug; 32(8):2690-703. PubMed ID: 25701313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.
    Shin MC; Zhang J; David AE; Trommer WE; Kwon YM; Min KA; Kim JH; Yang VC
    J Control Release; 2013 Nov; 172(1):169-178. PubMed ID: 23973813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction.
    Shin MC; Zhao J; Zhang J; Huang Y; He H; Wang M; Min KA; Yang VC
    J Biomed Mater Res A; 2015 Jan; 103(1):409-419. PubMed ID: 24733757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic engineering and characterisation of chlorotoxin-fused gelonin for enhanced glioblastoma therapy.
    Park T; Min KA; Cheong H; Moon C; Shin MC
    J Drug Target; 2019 Nov; 27(9):950-958. PubMed ID: 30156929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular tumor targeting of gelonin by fusion with F3 peptide.
    Ham SH; Min KA; Shin MC
    Acta Pharmacol Sin; 2017 Jun; 38(6):897-906. PubMed ID: 28414205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy.
    Polli JR; Chen P; Bordeau BM; Balthasar JP
    AAPS J; 2022 Mar; 24(3):47. PubMed ID: 35338415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.
    Ye J; Shin MC; Liang Q; He H; Yang VC
    J Control Release; 2015 May; 205():58-69. PubMed ID: 25483423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient Inhibition of Ovarian Cancer by Gelonin Toxin Gene Delivered by Biodegradable Cationic Heparin-polyethyleneimine Nanogels.
    Bai Y; Gou M; Yi T; Yang L; Liu L; Lin X; Su D; Wei Y; Zhao X
    Int J Med Sci; 2015; 12(5):397-406. PubMed ID: 26005374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment.
    Shin MC; Min KA; Cheong H; Moon C; Huang Y; He H; Yang VC
    Int J Pharm; 2017 May; 524(1-2):101-110. PubMed ID: 28359823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy.
    Ham S; Min KA; Yang JW; Shin MC
    Arch Pharm Res; 2017 Sep; 40(9):1094-1104. PubMed ID: 28900896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity.
    Shin MC; Min KA; Cheong H; Moon C; Huang Y; He H; Yang VC
    Pharm Res; 2016 Sep; 33(9):2218-2228. PubMed ID: 27251414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of hepatoma tumor growth by systemic administration of the phytotoxin gelonin driven by the survivin promoter.
    Wang Z; Zhou X; Li J; Liu X; Chen Z; Shen G; Guan T; Ye N; Wei X; Huang N; Yang L; Wei Y; Li J
    Neoplasma; 2013; 60(5):469-79. PubMed ID: 23790164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.
    Mujoo K; Cheung L; Murray JL; Rosenblum MG
    Cancer Immunol Immunother; 1995 May; 40(5):339-45. PubMed ID: 7600567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.
    Kim HS; Kim CH; Park MY; Park JS; Park HM; Sohn HJ; Kim HJ; Kim SG; Oh ST; Kim TG
    Immunol Lett; 2010 Jun; 131(1):73-80. PubMed ID: 20211203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell Penetrating Peptides Conjugated to Anti-Carcinoembryonic Antigen "Catch-and-Release" Monoclonal Antibodies Alter Plasma and Tissue Pharmacokinetics in Colorectal Cancer Xenograft Mice.
    Polli JR; Balthasar JP
    Bioconjug Chem; 2022 Aug; 33(8):1456-1466. PubMed ID: 35867869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts.
    Urva SR; Balthasar JP
    MAbs; 2010; 2(1):67-72. PubMed ID: 20081377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
    Rosenblum MG; Cheung LH; Liu Y; Marks JW
    Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of antiproliferative effects of monoclonal antibody Lym-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with gamma-interferon and tumor necrosis factor.
    O'Boyle KP; Colletti D; Mazurek C; Wang Y; Ray SK; Diamond B; Rosenblum MG; Epstein AL; Shochat D; Dutcher JP
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):221-30. PubMed ID: 8680650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.